Indicated to RAISE HDL-C
With a healthy diet and lifestyle
NIASPAN significantly RAISED HDL-C while lowering LDL-C and TG1
Results of 2 randomized, double-blind, parallel, placebo-controlled trials, where patients with primary hypercholesterolemia and mixed dyslipidemia received NIASPAN doses of 1000, 1500, or 2000 mg daily at bedtime with a low-fat snack for 16 weeks (including 4 weeks of dose escalation).
Results from two, randomized, double-blind, parallel, multicenter, placebo-controlled trials in patients with primary hypercholesterolemia and mixed dsylipidemia demonstrated that NIASPAN:1
- Significantly raised HDL-C up to 22% at two different doses
- Significantly lowered LDL-C and TG by as much as 14% and 28%, respectively
Nicotinic acid (niacin) is a very effective lipid-lowering drug for raising HDL levels.2
NIASPAN (niacin) is indicated:1
- As an adjunct to diet for reduction of elevated TC, LDL-C, Apo B, and TG levels and to increase HDL-C levels in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dsylipidemia (Frederickson Types IIa and IIb) when the response to an appropriate diet has been inadequate.
- In combination with lovastatin,
for the treatment of primary hypercholesterolemia (heterozygous familial
and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and
IIb) in:
- Patients treated with lovastatin who require further TG lowering or HDL-raising who may benefit from having niacin added to their regimen
- Patients treated with niacin who require further LDL-lowering who may benefit from having lovastatin added to their regimen
- To reduce the risk of recurrent nonfatal myocardial infarction in patients with a history of myocardial infarction and hypercholesterolemia
- In combination with a bile acid binding resin, to slow progression or promote regression of atherosclerotic disease in patients with a history of coronary artery disease and hypercholesterolemia
- In combination with a bile acid binding resin, as an adjunct to diet for reduction of elevated TC and LDL-C levels in adult patients with primary hypercholesterolemia (Type IIa) when the response to an appropriate diet, or diet plus monotherapy, has been inadequate.
Next: Combination Therapy and HDL-C
References
1. NIASPAN® prescribing information. North Chicago, IL; Abbott Laboratories.
2. National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Bethesda, MD: National Institutes of Health, US Dept of Health and Human Services, 2002. NIH Publication 02-5215.
